Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion

✍ Scribed by Richard L. Schilsky; Mark J. Ratain; Linda Janisch; Nicholas J. Vogelzang; V. Sol Lucas; Joshua Ravitch; John A. Hohneker; Neil J. Clendeninn; Richard L. Tuttle

• Publisher: Springer
• Year: 1993
• Tongue: English
• Weight: 703 KB
• Volume: 31
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/bf00685672